-all respondents think that both IGF-1 and GH are important for assessing biochemical control; most use GH<1.0 mcg/L as the local biochemical control criteria (in line with current guidelines) -there was consensus in the use of TSS as primary therapy • The survey also highlights some areas of variation and guideline recommendations not yet fully adopted; most notably the treatments that are used after failed surgery
• This survey relied upon clinical opinion of only 21 clinicians; nevertheless, it provides useful insights into the current management of acromegaly in the UK • The survey highlights some areas of consistency in management between centres:
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• The estimated number of new patients with acromegaly seen per year ranged between centres from 1-20 and the number of existing patients from 11-250.
• Most common referral sources for patients with acromegaly (not mutually exclusive) were other endocrinologists (14 respondents) and general practitioners (12 respondents).
Biochemical Control Criteria
Centre Characteristics
• All 21 survey respondents stated that both insulin-like growth factor 1 (IGF-1) and growth hormone (GH) are important for assessing biochemical control. how likely each would be to drive a medical management change. Visual disturbance and cardiomyopathy were most likely to drive changes in medical management (see Figure 5 ). • Other symptoms mentioned by respondents included sweating (n=8), sleep apnoea (n=6) and headache (n=6); the median rating was 4 for each symptom.
• Of the symptoms provided, enlargement of the face/feet/hands was reported to be the most common; cardiomyopathy and visual failure were reported as the least common. No.
respondents (n=21)

% patients
A. Second TSS
* One respondent commented that after early re-exploration, 99% of patients would have radiotherapy (at this centre most patients have a second surgical procedure, normally within 2 weeks of the first intervention; this is termed early re-exploration) ** One respondent commented (for all three treatments) that every decision depends on patient factors; for radiotherapy one commented that this depends on tumour size; for second TSS one commented that most patients have early re-exploration
• The estimated percentage of patients who receive TSS, radiotherapy or medical therapy as primary therapy is shown in Figure 3 .
INTRODUCTION
• Acromegaly is a rare endocrine disorder with an estimated prevalence of 1:140,000-1:250,000 1 .
• Treatment options include transsphenoidal surgery (TSS), medical management, radiotherapy or a combination of these, depending on disease and patient factors.
• In 2014 the Endocrine Society published clinical practice guidelines for the management of acromegaly 2 .
OBJECTIVE
• The objective of this survey was to obtain a snapshot of current UK practice following publication of the new guidelines.
METHODS
• A survey was undertaken of 21 endocrinologists from 19 secondary and tertiary care National Health Service centres in England (n=17), Scotland (n=1) and Wales (n=1).
• The surveys gathered information about current clinical management of acromegaly, local biochemical control criteria and the factors that drive treatment decisions.
• Endocrinologists with recognised interest and significant experience in the treatment of acromegaly were invited to participate by letter.
• Surveys were conducted by the Novartis Medical Science Liaison team between November 2014 and March 2015. Survey questions were validated by an endocrinologist.
RESULTS
CONCLUSIONS
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Second Line Treatments
• The estimated percentage of patients who receive a second TSS, radiotherapy or medical therapy after failure of primary surgical therapy is shown in Figure 4 .
• Medical management was the most common second line treatment (see Figure 4C ).
• There was considerable variation between centres in the reported proportion of patients who receive radiotherapy following surgical failure (see Figure 4B ).
